YVONNE MORRIS: Open Payments
NPI 1639863681 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 17 payments from 8 companies in 2025. Trend: 2023 $77 · 2024 $772 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $212 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| Lundbeck LLC | 2 | $43 |
| Indivior Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| ABBVIE INC. | 1 | $16 |
Products named: INGREZZA, REXULTI, SUBLOCADE, UZEDY, ABILIFY ASIMTUFII, CAPLYTA, INVEGA SUSTENNA, VRAYLAR.
Industry payments across VA — which companies pay providers there.
